Évaluation prospective du délai minimum de réalisation de l’IRM prostatique après une biopsie de prostate : facteurs prédictifs cliniques et anatomopathologiques de remaniements hémorragiques

Sarradin, M.; Lepiney, C.; Celhay, O.; Delpech, P.; Charles, T.; Pillot, P.; Bernardeau, S.; Tasu, Jean Pierre; Irani, Jacques

doi:10.1016/j.purol.2017.11.006

Cited by 4 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients underwent a standardized departmental MRI protocol on a 3T scanner (Discovery MR750w, General Electric Healthcare, Chicago, IL, USA) using a 16-channel pelvic anterior array coil (General Electric Healthcare, Chicago, IL, USA). The examination was performed before or at least eight weeks after the biopsy in order to reduce biopsyrelated impacts on MRI reading and PI-RADS score assessment, such as haemorrhage or inflammation [20]. The mpMRI protocol included the following: (1) T2-weighted (T2W) images on axial, sagittal, and coronal planes; (2) DWI on axial plane with automatically generated ADC maps; (3) T1-weighted (T1W) sequences on axial planes with and without fat saturation, acquired before and after intravenous gadolinium-based contrast.…”

Section: Mri Acquisitionmentioning

confidence: 99%

Towards the Definition of Radiomic Features and Clinical Indices to Enhance the Diagnosis of Clinically Significant Cancers in PI-RADS 4 and 5 Lesions

Bonaffini,

De Bernardi,

Corsi

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

Section: Mri Acquisitionmentioning

confidence: 99%

Towards the Definition of Radiomic Features and Clinical Indices to Enhance the Diagnosis of Clinically Significant Cancers in PI-RADS 4 and 5 Lesions

Bonaffini,

De Bernardi,

Corsi

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…In general, prostate MRI should not be performed within 8-12 weeks following prostate biopsy to allow sufficient time for resolution of blood products related to prostate biopsy, although large variations in presence and resolution of post-biopsy blood products in individual patients have been reported. [19][20][21] In the presence of blood products, prostate cancer can appear as hypointense area what some authors call as 'haemorrhage exclusion sign' which is defined as presence of a well-defined area of low signal intensity surrounded by areas of high signal intensity on T1-weighted images.…”

Section: Basics Of Mri Physics With Emphasis On Prostate Mrimentioning

confidence: 99%

How to read biparametric MRI in men with a clinical suspicious of prostate cancer: Pictorial review for beginners with public access to imaging, clinical and histopathological database

Jambor

Martini

Falagario

et al. 2021

Acta Radiologica Open

View full text Add to dashboard Cite

Prostate Magnetic Resonance Imaging (MRI) is increasingly being used in men with a clinical suspicion of prostate cancer (PCa). Performing prostate MRI without the use of an intravenous contrast (IV) agent in men with a clinical suspicion of PCa can lead to reduced MRI scan time. Enabling a large array of different medical providers (from mid-level to specialized radiologists) to evaluate and potentially report prostate MRI in men with a clinical suspicion of PCa with a high accuracy could be one way to enable wide adoption of prostate MRI in men with a clinical suspicion of PCa. The aim of this pictorial review is to provide an insight into acquisition, quality control and reporting of prostate MRI performed without IV contrast agent in men with a clinical suspicion of PCa, aimed specifically at radiologists starting reporting prostate MRI, urologists, urology/radiology residents and mid-level medical providers without experience in reporting prostate MRI. Free public access ( http://petiv.utu.fi/improd/ and http://petiv.utu.fi/multiimprod/ ) to complete datasets of 161 and 338 men is provided. The imaging datasets are accompanied by clinical, laboratory and histopathological findings. Several topics are simplified in order to provide a solid base for the development of skills needed for an unsupervised review and potential reporting of prostate MRI in men with a clinical suspicion of PCa. The current review represents the first step towards enabling a large array of different medical providers to review and report accurately prostate MRI performed without IV contrast agent in men with a clinical suspicion of PCa.

show abstract

PI‐RADS: Past, present, and future

Gupta

Mehta

Türkbey

et al. 2019

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Prostate cancer (PCa) is extremely prevalent and is the most common noncutaneous malignancy and second‐most common cause of cancer death in men. In the last decade, there has been dramatic growth in the use of multiparametric magnetic resonance imaging (mpMRI) for diagnosis and characterization of PCa. With the recent and marked surge in popularity in prostate imaging and, specifically, mpMRI, there has been an increased focus on structured reporting as a means by which to provide more actionable information to the referring clinician as well as to improve diagnostic performance with this technique. This work focuses on the evolution of the major structured reporting system in prostate mpMRI, Prostate Imaging Reporting And Data System (PI‐RADS), from its initial proposal and establishment in 2012 as PI‐RADS v. 1 to its most current iteration, PI‐RADS v. 2.1. This will highlight the key elements that have changed between the versions as well as provide context and rationale for these changes. In addition, this work explores what future iterations of PI‐RADS could look like based on current limitations of the system as well as explore areas for future growth of prostate mpMRI, including use of the system in active surveillance populations and in the posttreatment setting.Level of Evidence: 5Technical Efficacy: Stage 5J. Magn. Reson. Imaging 2020;52:33–53.

show abstract

Évaluation prospective du délai minimum de réalisation de l’IRM prostatique après une biopsie de prostate : facteurs prédictifs cliniques et anatomopathologiques de remaniements hémorragiques

Cited by 4 publications

References 20 publications

Towards the Definition of Radiomic Features and Clinical Indices to Enhance the Diagnosis of Clinically Significant Cancers in PI-RADS 4 and 5 Lesions

Towards the Definition of Radiomic Features and Clinical Indices to Enhance the Diagnosis of Clinically Significant Cancers in PI-RADS 4 and 5 Lesions

How to read biparametric MRI in men with a clinical suspicious of prostate cancer: Pictorial review for beginners with public access to imaging, clinical and histopathological database

PI‐RADS: Past, present, and future

Contact Info

Product

Resources

About